Smartleaf Asset Management
FATE icon

Smartleaf Asset Management’s Fate Therapeutics FATE Stock Holding History

Smartleaf Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$83 Hold
35
– – ﹤0.01% 3549
2026
Q2 		$85 Hold
35
– – ﹤0.01% 3374
2026
Q1 		$40 Hold
35
– – ﹤0.01% 3448
2025
Q4 		$34 Hold
35
– – ﹤0.01% 3450
2025
Q3 		$35 Hold
35
– – ﹤0.01% 2987
2025
Q2 		$36 Hold
35
– – ﹤0.01% 2706
2025
Q1 		$29 Buy
+35
New +$43 ﹤0.01% 2854
2024
Q4 		– Sell
-389
Closed -$1.39K – 2953
2024
Q3 		$1.39K Buy
+389
New +$1.51K ﹤0.01% 2581

Other funds holding FATE

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Smartleaf Asset Management's FATE Position: Q3 2026 in Review

Smartleaf Asset Management held its Fate Therapeutics (FATE) position steady in Q3 2026 at 35 shares worth $83. The position accounts for ﹤0.01% of the portfolio, ranked #3549.

Smartleaf Asset Management first reported a position in FATE in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.39K in Q3 2024. 55 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

  • Smartleaf Asset Management held 35 shares of Fate Therapeutics worth $83 as of Q3 2026.
  • Smartleaf Asset Management left its Fate Therapeutics share count unchanged in Q3 2026.
  • Fate Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #3549 holding.
  • Smartleaf Asset Management first reported a position in Fate Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Smartleaf Asset Management's Fate Therapeutics position peaked at $1.39K in Q3 2024.
  • 55 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.